NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
Cognitive–behavioural therapy delivered through the Improving Access to Psychological Therapies Programme did not achieve any clinical benefit in advanced cancer patients with depression
Abstract
Background:
With a prevalence of up to 16.5%, depression is one of the commonest mental disorders in people with advanced cancer. Depression reduces the quality of life (QoL) of patients and those close to them. The National Institute for Health and Care Excellence (NICE) guidelines recommend treating depression using antidepressants and/or psychological treatments, such as cognitive–behavioural therapy (CBT). Although CBT has been shown to be effective for people with cancer, it is unclear whether or not this is the case for people with advanced cancer and depression.
Objectives:
To assess the clinical effectiveness and cost-effectiveness of treatment as usual (TAU) plus manualised CBT, delivered by high-level Improving Access to Psychological Therapy (IAPT) practitioners, versus TAU for people with advanced cancer and depression, measured at baseline, 6, 12, 18 and 24 weeks.
Design:
Parallel-group, single-blind, randomised trial, stratified by whether or not an antidepressant was prescribed, comparing TAU with CBT plus TAU.
Setting:
Recruitment took place in oncology, hospice and primary care settings. CBT was delivered in IAPT centres or/and over the telephone.
Participants:
Patients (N = 230; n = 115 in each arm) with advanced cancer and depression. Inclusion criteria were a diagnosis of cancer not amenable to cure, a DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) diagnosis of depressive disorder using the Mini-International Neuropsychiatric Interview, a sufficient understanding of English and eligibility for treatment in an IAPT centre. Exclusion criteria were an estimated survival of < 4 months, being at high risk of suicide and receiving, or having received in the last 2 months, a psychological intervention recommended by NICE for treating depression.
Interventions:
(1) Up to 12 sessions of manualised individual CBT plus TAU delivered within 16 weeks and (2) TAU.
Outcome measures:
The primary outcome was the Beck Depression Inventory, version 2 (BDI-II) score at 6, 12, 18 and 24 weeks. Secondary outcomes included scores on the Patient Health Questionnaire-9, the Eastern Cooperative Oncology Group Performance Status, satisfaction with care, EuroQol-5 Dimensions and the Client Services Receipt Inventory, at 12 and 24 weeks.
Results:
A total of 80% of treatments (185/230) were analysed: CBT (plus TAU) (n = 93) and TAU (n = 92) for the BDI-II score at all time points using multilevel modelling. CBT was not clinically effective [treatment effect –0.84, 95% confidence interval (CI) –2.76 to 1.08; p = 0.39], nor was there any benefit for other measures. A subgroup analysis of those widowed, divorced or separated showed a significant effect of CBT on the BDI-II (treatment effect –7.21, 95% CI –11.15 to –3.28; p < 0.001). Economic analysis revealed that CBT has higher costs but produces more quality-adjusted life-years (QALYs) than TAU. The mean service costs for participants (not including the costs of the interventions) were similar across the two groups. There were no differences in EQ-5D median scores at baseline, nor was there any advantage of CBT over TAU at 12 weeks or 24 weeks. There was no statistically significant improvement in QALYs at 24 weeks.
Limitations:
Although all participants satisfied a diagnosis of depression, for some, this was of less than moderate severity at baseline, which could have attenuated treatment effects. Only 64% (74/115) took up CBT, comparable to the general uptake through IAPT.
Conclusions:
Cognitive–behavioural therapy (delivered through IAPT) does not achieve any clinical benefit in advanced cancer patients with depression. The benefit of CBT for people widowed, divorced or separated is consistent with other studies. Alternative treatment options for people with advanced cancer warrant evaluation. Screening and referring those widowed, divorced or separated to IAPT for CBT may be beneficial. Whether or not improvements in this subgroup are due to non-specific therapeutic effects needs investigation.
Trial registration:
Current Controlled Trials ISRCTN07622709.
Funding:
This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 19. See the NIHR Journals Library website for further project information.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Introduction
- Chapter 2. Objectives
- Chapter 3. Methods
- Acknowledgement
- Trial design and governance
- Eligibility criteria for participants
- Recruitment methods and procedures
- Set-up procedures
- Screening methods
- Randomisation
- Intervention
- Improving Access to Psychological Therapies involvement
- Quantitative assessment of delivery of cognitive–behavioural therapy
- Qualitative methods
- Chapter 4. Outcomes
- Chapter 5. Results
- Chapter 6. Health economics results
- Chapter 7. Discussion
- Chapter 8. Conclusions and implications for practice
- Acknowledgements
- References
- Appendix 1. Serious adverse events protocol
- Appendix 2. Topic guide: clinicians’ experiences
- Appendix 3. Topic guide: therapists’ experience
- Appendix 4. Topic guide: patients’ experience of cognitive–behavioural therapy
- List of abbreviations
About the Series
Article history
The research reported in this issue of the journal was funded by the HTA programme as project number 09/33/02. The contractual start date was in March 2012. The draft report began editorial review in May 2017 and was accepted for publication in January 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Declared competing interests of authors
Marc Serfaty is a member of the National Institute for Health Research Health Technology Assessment General Board.
Last reviewed: May 2017; Accepted: January 2018.
- NLM CatalogRelated NLM Catalog Entries
- Manualised cognitive–behavioural therapy in treating depression in advanced canc...Manualised cognitive–behavioural therapy in treating depression in advanced cancer: the CanTalk RCT
- A cost-effectiveness modelling study of strategies to reduce risk of infection f...A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review
- Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob dis...Interventions to reduce the risk of surgically transmitted Creutzfeldt–Jakob disease: a cost-effective modelling review
- Minimally invasive autopsy for fetuses and children based on a combination of po...Minimally invasive autopsy for fetuses and children based on a combination of post-mortem MRI and endoscopic examination: a feasibility study
- Standard threshold laser versus subthreshold micropulse laser for adults with di...Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT
Your browsing activity is empty.
Activity recording is turned off.
See more...